 |
The Centre for PET at the Austin Hospital has facilities available to pharmaceutical companies to assist with pre-clinical and clinical trial drug studies and development.
Also, the radiochemistry group is the leading group in Australasia for PET isotope and ligand development, particularly for 11C chemistry and 18F ligand development.
|
Accelerate Drug Development with Quantitative PET
The unique advantage of PET is its ability to produce both high resolution images and accurate
quantitative pharmacodynamic and pharmacokinetic measurements in vivo. This makes PET an ideal tool for pre-clinical drug trialing.
After a drug has been approved for human use, PET can assist in pre-clinical evaluation of the drug therapy by:
- Mapping the distribution of a new drug through the human body;
- Establishing the drug's efficacy in reaching its intended site of action;
- Measuring the drug's specificity of the intended receptors in vivo; and
- Identifying metabolic and binding characteristics in the human body that differ from those predicted from animal models.
By providing accurate information about each of these aspects of a new drug PET can:
- Expedite the decision on whether to proceed with further development of the drug;
- Identify previously unknown in vivo receptor and metabolic characteristics; and
- Help evaluate pharmacokinetics and pharmacodynamics of new drugs in normal humans or subjects with defined illnesses.
|
|
|
